Rungroj KrittayaphongBancha SatirapojBoonsong OngphiphadhanakulKriengsak VareesangthipSompongse SuwanwalaikornWacin BuddhariMahidol UniversityPhramongkutklao College of MedicineFaculty of Medicine, Chulalongkorn University2022-08-042022-08-042021-11-01Journal of the Medical Association of Thailand. Vol.104, No.11 (2021), 1850-1865012522082-s2.0-85120625176https://repository.li.mahidol.ac.th/handle/123456789/77696Background: Cardiovascular (CV) and renal comorbidities are common among type 2 diabetes (T2D) patients, and significantly increase the cost and burden of care. Both sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve key outcomes including major CV events, hospitalization for heart failure, and renal outcomes, albeit to varying degrees in different T2D populations. Materials and Methods: The authors reviewed evidence from GLP-1 RA and SGLT2i CV outcomes trials and real-world studies in Thailand and elsewhere. Results: The authors formulated recommendations to guide selection of anti-diabetes medication based on patients clinical characteristics and CV or renal risk profile. Conclusion: These recommendations could help guide management of CV/renal comorbidities and risk alongside glucose-lowering therapy for individual patients.Mahidol UniversityMedicineReviewSCOPUS10.35755/jmedassocthai.2021.11.13163